Introduction: Financial toxicity (FT) is a nonspecific term used to characterize the self-reported economic consequences resulting from a medical problem. We aim to characterize the FT associated with the management of benign prostatic hyperplasia (BPH) in a private practice setting. Methods: A cross-sectional assessment of FT in all men being actively managed for BPH was performed using The Comprehensive Score for Financial Toxicity - Functional Assessment of Chronic Illness Therapy (COST-FACIT-2). All patients at Urology of Virginia from September to October 2022 were given the FACIT-2 survey while filling out their intake paperwork. The questionnaire has 12 items with 11 scorable categories for a total range of 0-44. FT grade 0-3 was calculated with a higher score indicating a lower grade of FT. Results: A total of 635 patients diagnosed with BPH completed the survey. A total of 28% of men reported at least moderate financial toxicity associated with their BPH management. There was a statistically significant correlation between increasing age of patient and decreasing degree financial toxicity (P= 0.020, R2). While on average, individuals with one episode of urinary retention reported worse financial toxicity, this was not statistically significant (P= 0.0516). Conclusions: This study identifies that in the setting of a private practice with insured patients, there remains significant financial distress in the management of their BPH management. With a multitude of management options for BPH available, further investigation into whether definitive surgical intervention versus medical management will impact a self-perceived financial distress. SOURCE OF Funding: None
